Gigagen Incis A Biotechnology Company Based In San Carloscaliforniaand A Subsidiary Of Grifolsthe Company Specializes In Antibody Drug Discovery And Developmentfocusing On Addressing Immune Deficienciesinfectious Diseasesand Checkpoint Resistant Cancerswith A Team Of 39 Employeesgigagen Reported An Annual Revenue Of $5 6 Million In 2025 The Company Employs Advanced Single Cell Technologies To Replicate And Engineer The Natural Diversity Of Human Antibodiestheir Proprietary Platforms Include Machine Learning Driven Antibody Discoverywhich Accelerates Therapeutic Development By Predicting And Generating Antibody Sequencesgigagen Is Actively Developing Recombinant Antibody Therapieswith A Pipeline That Includes Treatments For Infectious Diseasesoncologyand Immune Deficienciesthey Have Achieved Significant Clinical Milestonesincluding Gmp Manufacturing And Ind Enabling Studiesand Hold Over 50 Global Patentsgigagen Collaborates With The U Sdepartment Of Defense And Engages In Partnerships Within The Biopharma Sector
